Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S.
Biontech Se (BNTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Logos Capital Arsani William | 1,015,000 | $94,445,750 | 4.07% | |
| 2. | Long Focus Capital Management John B. Helmers | 624,000 | $58,063,200 | 1.48% | |
| 3. | Tang Capital Management Kevin C. Tang | 470,000 | $43,733,500 | 1.99% | |
| 4. | Balyasny Asset Management Dmitry Balyasny | 463,163 | $43,097,317 | +396% | 0.05% |
| 5. | D E Shaw D. E. Shaw | 417,421 | $38,841,024 | +109% | 0.02% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $98.12 | 32,000 | $3,139,849.60 | 214,209 | 2026-09-30 | Filing | |
| $98.26 | 34,000 | $3,340,809.40 | 246,209 | 2026-09-29 | Filing | |
| $98.47 | 34,000 | $3,347,918.80 | 280,209 | 2026-09-28 | Filing | |
| $98.69 | 27,000 | $2,664,581.40 | 314,209 | 2026-09-25 | Filing | |
| $98.99 | 39,000 | $3,860,660.70 | 341,209 | 2026-09-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,571,805 | $704,556,470 | 0.03% | |
| 2. | 3,772,031 | $350,987,486 | 0.21% | |
| 3. | 3,677,591 | $342,199,843 | 0.18% | |
| 4. | 2,226,138 | $207,142,141 | 0.94% | |
| 5. | 1,854,966 | $172,604,590 | 0% |
News See All
Anthropic Builds San Francisco Biology Lab to Advance AI Drug Development
Anthropic built a real biology lab in the San Francisco Bay Area to test its artificial intelligence for making new medicines, according to an excl...
Tempus AI Stock (TEM) Surges 40% in a Week — Is More Upside Ahead?
Shares of Tempus AI ($TEM) jumped 15% Thursday, extending their five-day gain to nearly 40%. The rally came after CEO Eric Lefkofsky outlined the c...
BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic...
BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?
BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was unlikely...
BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why
BioNTech ($BNTX) shares declined as much as 10% on Friday after the company said it has ended a key Phase 2 trial for its mRNA colorectal cancer va...
BioNTech (BNTX) Rallied on Moderna’s Win. Does a Competitor’s Success Validate its Oncology Pipeline?
BioNTech SE (NASDAQ:BNTX) rallied following the first positive interim Phase 3 topline result for a personalized mRNA cancer therapy.
Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update
Pfizer stock was up 3.74% thanks to a clinical trial update from Merck and Moderna that showed the potential of an MRNA vaccine as a cancer treatme...
Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements.
Is BioNTech SE (BNTX) A Good Stock To Buy Now?
Is BNTX a good stock to buy? We came across a bullish thesis on BioNTech SE on r/ValueInvesting by birdflustocks. In this article, we will summarize the bulls’ thesis on BNTX.
Hedge Fund Resource Center